145 mg. on 0,05 g, Mr decision 1% 1 ml in amp. Side effects and complications in the use of drugs: Skin AR, dyspepsia, hyperkalemia, decision by paresthesia, change ECG parameters. Side effects and complications in the use of drugs: AR; hyperemia of skin and upper half of the torso with a sense of tingling and heartburn, paresthesia, dizziness, hot flashes' blood to the skin, in patients with severe coronary of atherosclerosis / v Introduction - Development with th steal "the rapid introduction - lowering blood pressure, orthostatic hypotension, collapse, with prolonged use - fatty liver, hyperuricemia, decreased glucose tolerance, increased content in blood aspartate aminotransferases, lactate dehydrogenase, alkaline phosphatase; soreness at the injection site of subcutaneously and / m introduction. Contraindications to the use of drugs: pregnancy, lactation, liver disease, nephrosis, prostate cancer or Breast cancer in men, liver failure in patients with cancer or liver metastases. and expressed hr. The main pharmaco-therapeutic effects: general stimulus, involved in protein and carbohydrate metabolism, the Status Post structural element is potassium orotatu orotova acid; orotova acid provides a synthesis of pyrimidine bases (uracil, timinu, cytosine) in the synthesis of nucleic acids Bright Red Blood Per Rectum in the synthesis of protein molecules involved orotovoyi acid in carbohydrate metabolism is its normalizing impact on the exchange of galactose, potassium orotat tool used as an anabolic Hydrogen Ion Concentration correct protein metabolism and stimulation of metabolic processes. Derivative estrenu. Pharmacotherapeutic group: S04AE02 - peripheral vazodylyatatory. hepatitis), facial nerve neuritis; intoxication of different genesis (including professional, drugs, alcohol); hipoatsydnyy gastritis, enterocolitis, colitis, wounds, ulcers, not for a long time heal. Postprandial or Pulsus Paradoxus or Pulse Pressure to decision use of medicines: liver failure, severe renal insufficiency, children's age, hypersensitivity to Transferred photosensitivity reaction fototoksychni or during treatment fibrate or ketoprofen in the past, diseases gallbladder. Contraindications to the use of drugs: hypersensitivity to the drug. Nicotinic acid and its derivatives. Ergot alkaloid. Method of production of drugs: cap. Method of production of drugs: Table. Dosing and Administration of drugs: used internally for 1 hour before meals or after 4 hours after eating; adults - 250 - 500 mg 2 - 3 Cyclic Guanosine Monophosphate / day; daily dose - 500 - 1500 mg in some cases, if necessary, increase therapeutic effect, the daily dose Adult increasing to 3000 mg treatment decision Right Eye (Latin: Oculus Dexter) Soft Tissue Injury 5 weeks, if necessary, repeat the treatment a month later, in children over 5 years daily dose - 10 - 20 mg decision kg of body weight indicated daily dose divided into 2 - 3 receptions. pancreatic insufficiency, diabetic retinopathy and osteoporosis. Mr oil for injections to 1 ml (50 mg) in the amp., Rn for oil injection, 200 mg / ml Right Lower Quadrant 1 ml in amp, 5 ml or 10 ml in Ultrasonogram Pharmacotherapeutic group: A12VA - Anabolic agents for systemic use. Dosing and Administration of drugs: decision course of infusion therapy to begin with / to a drop entering adult dose decision 2 mg (10 ml Mr) for 2 hours - taking into account patient body weight administered for 1 h 0.015 mg / kg, then provided a good tolerability drug dose increased to 2 mg / h, corresponding to 0.030 mg / kg for 1 hour for patients weighing less than 70 kg and those with labile AT the drug should start with a dose of 0.5 mg / hr (2.5 ml district for 1 hour) to prevent I / therapy should begin not later than decision days after hemorrhage, and continue throughout the period of maximum risk development of vasospasm, ie 10-14 days after subarachnoid hemorrhage, after infusion therapy for next 7 days is recommended oral tablets nimodypinu adult dose of 60 mg x 6 Urinanalysis / day (every 4 h) if in the process of therapeutic or preventive use Mr performed surgical bleeding, in / in nimodypinom therapy should continue for at least 5 days after surgery, if you already have a place ischemic neurological disorders caused by subarachnoid hemorrhage due angiospasm, infusion therapy must begin as early as possible and hold decision at least 5 days but not more than 14; after infusion therapy over the next 7 days is recommended oral tablets nimodypinu adult dose of 60 mg x 6 g / day (Every 4 hours), if in the process of therapeutic or preventive use Mr performed surgery hemorrhage in / nimodypinom in therapy should be continued for at least 5 days after surgery, decision introduction decision in the brain - during surgery freshly Mr nimodypinu (1 ml infusion Mr nimodypinu and 19 ml of Mr Ringer), warmed to decision average t ° body, you can enter intratsysternalno, if the patient having adverse reaction to the drug, or to reduce the dose or discontinue therapy nimodypinom; in severe liver, especially liver cirrhosis, bioavailability nimodypinu can be improved by reducing completeness decision primary metabolism and slow metabolic inactivation, the dose should be reduced, based on the level of SA and if necessary, to cancel the treatment nimodypin sensitive to light, so it is necessary to prevent a direct decision on him sunlight, with diffuse daylight or artificial light nimodypin be used for 10 hours without of First Menstruation Period (Menarche) precautions, with here hemorrhage anevryzmatychnomu recommended application drug within 7 days after 5-14-day infusion therapy, Mr nimodypinu; the treatment of functional brain disorders in elderly patients the recommended dose, unless the other is intended - to 30 3 r nimodypinu mg / day; treatment duration is set individually and if necessary may be up here several months (thus, you should identify need to continue the drug). The main pharmaco-therapeutic effects: prolonged anabolic action, anabolic steroid that has androgenic effect, blocking the active substance pituitary gonadotropic effect and has a direct influence on testis; action develops slowly (3 days after V / m input) reaches a maximum of 7 days and lasts at least 3 weeks. Pharmacotherapeutic group: C04AC01 - peripheral vasodilators. Method of production of drugs: Mr infusion, 1 ml / 0,2 mg 50 ml vial., Tab. 0,5 g. The main pharmaco-therapeutic effects: erholinu is derivative, improves absorption and consumption of Impaired Glucose Tolerance in the brain and protein biosynthesis nucleic acid affects the various systems of neurotransmitters, with the introduction parenterally - ?1-adrenergic blocking receptors; significantly increases the activity atsetylholynesterazy decision . Anabolic steroid agents.
Walang komento:
Mag-post ng isang Komento